Find what you were looking for? Share your thoughts with a short survey

Diabetes, Endocrinology, Nutrition, Obesity, Vision and Related Services

Diabetes, Endocrinology, Nutrition, Obesity, Vision and Related Services (DENOVARS) Clinical Academic Group (CAG) comprises the largest centre for metabolic disease in Europe.


Our CAG brings together a range of services including newly diagnosed Type 1 and 2 diabetes, diabetic eye complication screening, liaison psychiatry, pre-pregnancy care, a full range of podiatric services and treatments, supportive orthotic services, educational programmes for diabetes management, islet transplantation, Dose Adjusted for Normal Eating (DAFNE) programme for Type 1 diabetes, insulin pump therapy and lipid management. We provide specialist support for diabetes in every practice in Lambeth and Southwark, and many in Wandsworth.

Read the latest news from our Diabetes, Endocrinology, Nutrition, Obesity, Vision and Related Services CAG.

Through our Institute of Diabetes, Obesity and Endocrinology we are working collaboratively to deliver a world-class clinical, research, and education offer that directly improves quality and access to diabetes, obesity and endocrinology care, achieves parity across mental and physical health, and leads the development of highly innovative solutions that support prevention, better self-management of care, and reduced episodes of health deterioration.

Clinical strengths

Our CAG is focusing on the management of long-term conditions particularly community and primary care integration, together with involving patients and carers more in service design.

Our strengths include the leading centre for management of Type 1 diabetes and hypoglycaemia in the UK, with more than 500 patients on insulin pumps. We are also one of the seven national islet transplantation centres.

We are piloting the 3 Dimensions for Care for Diabetes (3DFD) programme for Lambeth and Southwark residents targeting people with difficult to control diabetes. Alongside, we are developing world class bariatric surgery pathways and supporting the development of effective interventions in the community for obesity related problems.


We have e-learning packages through the Health Innovation and Education Cluster on the relationship between depression and diabetes, and diabetes self-management.


Our particular research interests include developing a better understanding of Type 1 diabetes, immunity, islet storage preservation and biology. We are currently in the process of testing novel forms of nano and macroencapsulation strategies applying innovative immunoproductive materials in combination with oxygenated devices. This will have the potential to revolutionise the field of regenerative therapies for diabetes.

We are also combining diabetes and mental disease research to explore and understand the shared biology of diabetes and depression, and to develop appropriate treatment algorithms for the future.

Innovations and achievements

  • Read about how our clinical academic collaborations are improving the lives of our patients in Innovation Impact Stories
  • See 70 examples of key achievements from across our partnership in our CAGraphics booklet.
Our aim is to be ambassadors for healthier living and utilise the full capacity within King’s Health Partners to promote healthier nutrition and lifestyles in the local population and the local health workforce. Diabetes and metabolic disease has been identified as one of the major threats to economic growth and development on a global level according to the World Economic Forum. We are committed to take a lead in addressing this challenge through cutting edge innovation, translational research and comprehensive patient management from prevention to tertiary care. With existing programmes in metabolic neuroimaging, mental health, obesity management and in beta cell physiology, growth and replacement - including islet transplantation – our translational programme will range from developing new treatments to improve weight and diabetes control, through preservation of insulin secretion in type 2 diabetes, to new surgical approaches to manage extreme obesity.
Professor David Hopkins, Professor Khalida Ismail and Dr Stephen Thomas - joint DENOVARS CAG Leaders


Professor David Hopkins, Consultant Physician & Clinical Director, King's College Hospital NHS Foundation Trust

Professor Khalida Ismail, Professor of Psychiatry and Medicine, King's College London

Dr Stephen Thomas, Consultant in Diabetes and Endocrinology, Guy’s and St Thomas’s NHS Foundation Trust